What is Recardio?
Recardio operates at the intersection of biotechnology and cardiology, focusing on the development of breakthrough therapeutic candidates designed to stimulate cardiac regeneration. The company's primary asset, dutogliptin, represents a significant shift in how clinicians approach heart tissue repair and healing. By leveraging innovative molecular pathways, Recardio is positioning itself as a pivotal player in the life sciences sector, moving beyond traditional symptom management toward curative interventions. Their strategic collaborations with pharmaceutical industry leaders further validate their clinical methodology and operational maturity as they navigate the complexities of late-stage clinical trials.
How much funding has Recardio raised?
Recardio has raised a total of $11M across 1 funding round:
Series A
$11M
Series A (2016): $11M, investors not publicly disclosed
Key Investors in Recardio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Recardio?
With this major enterprise-level funding, Recardio is well-positioned to scale its clinical evaluation programs and refine its manufacturing processes for dutogliptin. The company's roadmap focuses on achieving key regulatory milestones and expanding its intellectual property portfolio to maintain a competitive edge in the regenerative medicine market. As the firm transitions toward potential commercialization, the focus will likely shift to optimizing patient outcomes and securing long-term partnerships that facilitate global market access. Investors and industry stakeholders will be closely monitoring the upcoming data readouts, which are expected to serve as a catalyst for the company's next phase of growth and potential strategic exit opportunities.
See full Recardio company page
